Secunderabad Chronicle

Rhinitis Pipeline as Novel and Extensive 35+ Therapies Likely to Enter in the Treatment Domain

 Breaking News
  • No posts were found

Rhinitis Pipeline as Novel and Extensive 35+ Therapies Likely to Enter in the Treatment Domain

December 08
10:04 2022
Rhinitis Pipeline as Novel and Extensive 35+ Therapies Likely to Enter in the Treatment Domain

DelveInsight’s, “Rhinitis Pipeline Insight, 2022,” report provides comprehensive insights about 35+ companies and  35+ pipeline drugs in the Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Rhinitis Pipeline Report

  • DelveInsight’s Rhinitis Pipeline report depicts a robust space with 35+ active players working to develop 35+ pipeline therapies for Rhinitis.
  • The leading Rhinitis Pipeline Companies are working such as Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals Inc, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO.Ltd, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others.
  • Promising Rhinitis Pipeline Therapies such as Lactobacillus paracasei LP-33, Observational, Levocetirizine, BLX-028914, AD17002, Nasapaque Nasal Solution, Mometasone Furoate Nasal Spray, 50 mcg, MK-8237 tablets, MK-8237 6 DU, and others.
  • In the coming years, the Rhinitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The Rhinitis Companies and academics that are working to assess challenges and seek opportunities that could influence Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Recent Developmental Activities in the Rhinitis Pipeline Insight Report

  • REGN1908-1909 is a novel cocktail of two fully-human monoclonal IgG antibodies, designed to specifically bind and block the Fel d 1 allergen, thus preventing it from binding and triggering the endogenous antibodies that cause allergies (i.e., Immunoglobulin E, or IgE, antibodies). REGN1908-1909 was invented using Regeneron’s proprietary VelocImmune® technology. Currently, it is in phase III stage of clinical trial evaluation to treat Allergic Rhinitis Due to Cat Allergy.
  • IRL201104 was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It is expected to provide long-term remission for many allergic diseases. IRL201104 has been shown to quickly and markedly reduce lung infiltration of neutrophils in mice following bronchial challenge with lipopolysaccharide stimulating acute neutrophil activation.  IRL1104 has a very short circulation exposure following IV administration and acts on neutrophil infiltration quickly but in a transient manner, which may mean that it would be able to provide a marked, but temporary, reduction in lung neutrophilia, potentially allowing the lung some respite from the high level of inflammation. Currently, it is in phase II stage of clinical trial evaluation to treat Seasonal Allergic Rhinitis.

 

Get an overview of the Rhinitis Clinical Trials @ Rhinitis Pipeline Outlook Report

 

Rhinitis Overview

Rhinitis is a condition that typically involves nasal obstruction or congestion, runny nose or post-nasal drip, itchy nose, and/or sneezing. There are various causes for these symptoms, although they are broadly divided into two types: allergic rhinitis (nasal symptoms related to allergy) and non-allergic rhinitis (nasal symptoms that are not related to allergy). Rhinitis may occur before a case of sinusitis or with sinusitis, a condition where infection or inflammation affects the sinuses. If you have facial pressure, decreased sense of smell, or a greenish-yellow nasal drainage, you may also have sinusitis. A qualified ENT (ear, nose, and throat) specialist, or otolaryngologist, can provide a thorough evaluation and appropriate treatment for your nasal/sinus condition.

 

Rhinitis Pipeline Insight Report

In the Rhinitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Rhinitis Emerging Drugs Profile

  • REGN1908-1909: Regeneron
  • IRL201104: Revolo Biotherapeutics

 

Rhinitis Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the therapies for Rhinitis. The companies which have their Rhinitis drug candidates in the most advanced stage, i.e. phase III include, Regeneron.

 

Request a sample and discover the recent advances in Rhinitis Treatment Drugs @ Rhinitis Ongoing Clinical Trials Analysis

 

Scope of the Rhinitis Pipeline Insight Report

  • Coverage- Global
  • Rhinitis Pipeline Companies are working such as Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals Inc, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO.Ltd, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others.
  • Rhinitis Pipeline Therapies such as Lactobacillus paracasei LP-33, Observational, Levocetirizine, BLX-028914, AD17002, Nasapaque Nasal Solution, Mometasone Furoate Nasal Spray, 50 mcg, MK-8237 tablets, MK-8237 6 DU, and others

 

Table of Content

  1. Introduction
  2. Rhinitis Executive Summary
  3. Rhinitis: Overview
  4. Rhinitis Pipeline Therapeutics
  5. Rhinitis Therapeutic Assessment
  6. Rhinitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. REGN1908-1909: Regeneron
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IRL201104: Revolo Biotherapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Rhinitis Key Companies
  21. Rhinitis Key Products
  22. Rhinitis- Unmet Needs
  23. Rhinitis- Market Drivers and Barriers
  24. Rhinitis- Future Perspectives and Conclusion
  25. Rhinitis Analyst Views
  26. Rhinitis Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Rhinitis drugs?
  • How many Rhinitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rhinitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rhinitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Rhinitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Rhinitis Pipeline therapeutics, reach out to Rhinitis Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles